A Single Blind Study to Evaluate the Safety, Tolerability and Explore the Efficacy of 8.0 mg ASM8 Inhaled Daily for 14 Days in Severe Asthma
NCT01380236
·
clinicaltrials.gov ↗
PHASE2
Phase
WITHDRAWN
Status
INDUSTRY
Sponsor class
Stopped
Protocol not progressed. Study not implemented.
Conditions
Asthma
Interventions
DRUG:
ASM8
Sponsor
Syntara